Sunstone Life Science Fund II portfolio Company VAXIMM AG, a Swiss/German biotech company focused on developing oral T-cell immunotherapies, today announced that the first clinical data in glioblastoma with its lead product candidate, oral VXM01, are being presented at the upcoming American Society of Clinical Oncology (ASCO) 2017 Annual Meeting being held June 2-6, 2017 in Chicago, IL, USA.